News

NIH Awards Ceres Nanosciences $8.2M for Wastewater-Based COVID-19 Surveillance

Ceres Nanosciences announced it has been awarded an $8.2 million contract from the National Institutes of Health’s Rapid Acceleration of Diagnostics Initiative. The funding will support the development and implementation of wastewater-based surveillance systems for COVID-19.

Manassas, Virginia-based Ceres plans to develop surveillance systems using its Nanotrap particle technology at a network of sites, with an emphasis on underserved and vulnerable populations.

In a statement, Ceres noted that wastewater surveillance can be used to monitor trends in SARS-CoV-2 infection at a population level, but that “widespread implementation has been stymied by the lack of a sensitive, rapid, high-throughput viral concentration method.”

The firm’s Nanotrap Magnetic Virus Particles can capture and concentrate viruses directly from raw sewage prior to RNA extraction, according to Ceres, and this workflow can be adapted for small- and large-scale surveillance systems.

As part of the new funding, Ceres will work with researchers at Emory University to develop and implement a wastewater-based COVID-19 surveillance system in the metro-Atlanta area “with a focus on use cases for underserved and vulnerable populations,” such as correctional facilities, low-income neighborhoods, and long-term care facilities, the firm said.

Christine Moe, a wastewater infectious disease researcher at Emory, said that the collaboration between Ceres and the university will generate “robust evidence” to support the US Center for Disease Control and Prevention’s objective of developing a national wastewater surveillance system that “meets the information needs of city, county, and state decision makers to effectively respond to the COVID-19 pandemic across multiple use cases in underserved community settings.”

In parallel to this collaboration, Ceres will also be identifying and launching a network of “centers of excellence” for high-throughput wastewater-based COVID-19 surveillance.

Ben Lepene, Ceres’s chief technology officer, noted that researchers from the University of California, San Diego recently described a Nanotrap particle high-throughput method for wastewater surveillance that can process more than 100 samples in a day “with an ability to detect one asymptomatic infected individual in a building with 415 residents.” The firm expects to identify additional sites in the US to implement similar approaches.

Last year, Ceres was awarded $6.6 million from RADx to increase the manufacturing capacity of its Nanotrap Magnetic Virus Particles. The Nanotrap technology has also been also utilized for SARS-CoV-2 and Lyme disease diagnostics, as well as in liquid biopsy applications.

Recent News

04/24/2026

Skyphos Technologies Has Been Awarded its Second U.S. Patent

Skyphos Technologies has been awarded its second U.S. patent, adding to a growing intellectual property portfolio that now includes nearly a dozen patent applications in process around the world. This latest patent secures core technologies and methods that allow micro-scale parts to be produced in seconds, at throughputs designed to exceed legacy manufacturing such as

04/23/2026

CollectiveMinds LLC Places Keith Meadors as Chief Commercial Officer at Genova Diagnostics

CollectiveMinds LLC, a leading executive search firm specializing in life sciences and healthcare, today announced the successful placement of Keith Meadors as Chief Commercial Officer of Genova Diagnostics, a pioneer in advanced diagnostic testing. The appointment marks another milestone for CollectiveMinds in connecting exceptional leadership talent with high-growth organizations across the diagnostics and life sciences

04/22/2026

RIVANNA expands multi-site clinical study for Accuro XV musculoskeletal imaging system

RIVANNA®, developer of AI-enabled clinical decision-support solutions, announced that it has expanded its clinical studies evaluating Accuro® XV, the company’s musculoskeletal imaging system, from two to eight sites nationwide. This expansion follows execution of a funding option by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response